Toll Free: 1-888-928-9744

Foamix Ltd. - Product Pipeline Review - 2014

Published: Sep, 2014 | Pages: 40 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Foamix Ltd. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Foamix Ltd. - Product Pipeline Review - 2014', provides an overview of the Foamix Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Foamix Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Foamix Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Foamix Ltd.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Foamix Ltd.'s pipeline products

Reasons to buy

- Evaluate Foamix Ltd.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Foamix Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Foamix Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Foamix Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Foamix Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Foamix Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Foamix Ltd. Snapshot 5
Foamix Ltd. Overview 5
Key Information 5
Key Facts 5
Foamix Ltd. - Research and Development Overview 6
Key Therapeutic Areas 6
Foamix Ltd. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Foamix Ltd. - Pipeline Products Glance 13
Foamix Ltd. - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Foamix Ltd. - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Foamix Ltd. - Unknown Stage Pipeline Products 16
Unknown Products/Combination Treatment Modalities 16
Foamix Ltd. - Drug Profiles 17
permethrin 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
clobetasol propionate 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
doxycycline 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
minocycline 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
mometasone furoate 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
acyclovir 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
benzoyl peroxide 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
betamethasone dipropionate 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
calcipotriene 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
ciclopirox olamine 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
estradiol hemihydrate 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
imiquimod 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
salicylic acid 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
triamcinolone acetonide 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
minocycline Gel 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Foamix Ltd. - Pipeline Analysis 33
Foamix Ltd. - Pipeline Products by Target 33
Foamix Ltd. - Pipeline Products by Route of Administration 34
Foamix Ltd. - Pipeline Products by Molecule Type 35
Foamix Ltd. - Pipeline Products by Mechanism of Action 36
Foamix Ltd. - Recent Pipeline Updates 37
Foamix Ltd. - Locations And Subsidiaries 38
Head Office 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40
List of Tables
Foamix Ltd., Key Information 5
Foamix Ltd., Key Facts 5
Foamix Ltd. - Pipeline by Indication, 2014 7
Foamix Ltd. - Pipeline by Stage of Development, 2014 9
Foamix Ltd. - Monotherapy Products in Pipeline, 2014 10
Foamix Ltd. - Partnered Products in Pipeline, 2014 11
Foamix Ltd. - Partnered Products/ Combination Treatment Modalities, 2014 12
Foamix Ltd. - Phase II, 2014 13
Foamix Ltd. - Phase I, 2014 14
Foamix Ltd. - Preclinical, 2014 15
Foamix Ltd. - Unknown, 2014 16
Foamix Ltd. - Pipeline by Target, 2014 33
Foamix Ltd. - Pipeline by Route of Administration, 2014 34
Foamix Ltd. - Pipeline by Molecule Type, 2014 35
Foamix Ltd. - Pipeline Products by Mechanism of Action, 2014 36
Foamix Ltd. - Recent Pipeline Updates, 2014 37 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify